HC Wainwright Reaffirms Buy Rating for MoonLake Immunotherapeutics (NASDAQ:MLTX)

MoonLake Immunotherapeutics (NASDAQ:MLTX – Get Free Report)‘s stock had its “buy” rating reissued by stock analysts at HC Wainwright in a research report issued to clients and investors on Thursday, Benzinga reports. They currently have a $100.00 target price on the stock. HC Wainwright’s price objective points to a potential upside of 116.54% from the […]

Related Keywords

Switzerland ,Stifel Nicolaus ,Kristian Reich ,Silva Jorge Santos ,Moonlake Immunotherapeutics ,Goldman Sachs Group ,Wolfe Research ,Moonlake Immunotherapeutics Company Profile ,Nasdaq ,Needham Company ,Citadel Advisors ,Pricet Rowe Associates Inc ,Securities Exchange Commission ,Avoro Capital Advisors ,Get Free Report ,Exchange Commission ,Capital Advisors ,Adage Capital Partners ,Capital Partners ,Nasdaq Mltx ,Mltx ,Medical ,Reiterated Rating ,Hc Wainwright ,